

## **IN THE CLAIMS:**

Applicant's note that the Examiner has renumbered previously cancelled claims 1-4 and 9-20 as claims 1-16 and renumbered claims 21-47 as claims 17-43. Please cancel claims 19 and 30-43 without prejudice to Applicant's right to pursue the subject matter of the canceled claims in one or more continuation, continuation-in-part, or divisional applications. Please amend claims 17-18 and 20-29 as indicated below. In compliance with 37 C.F.R. § 1.121, a complete listing of the claims is presented below. For currently amended claims deleted language is shown by strikethrough or brackets and added language is shown by underlining. No new matter has been added.

### Claims 1-16 (cancelled)

17. (currently amended) A method for treating a vascular disease or condition selected from the group consisting of atherosclerosis, ~~hyperlipidemia~~ hypercholesterolemia and hypoalphalipoproteinemia in a human, comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes having empty aqueous cores and having a Gaussian distribution wherein at least about 68% of the liposomes have a mean diameter of  $125 \pm 30$  nm.

18. (currently amended) ~~The method of claim 21~~ A method for treating a vascular disease or condition selected from the group consisting of atherosclerosis, hypercholesterolemia and hypoalphalipoproteinemia in a human, comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes having empty aqueous cores and having a Gaussian distribution wherein at least about 68% of the liposomes have a mean diameter between 100-150 nm.

### Claim 19 (canceled)

20. (currently amended) The method of claim ~~21~~ 17 or 18 in which the therapeutically effective amount is ~~in the range of~~ about 10 mg to about 1600 mg per kg body weight.

21. (currently amended) The method of claim ~~21~~ 17 or 18 in which the therapeutically effective amount is about 300 mg per kg body weight.

22. (currently amended) The method of claim ~~21~~ 17 or 18 in which the therapeutically effective amount is about 0.1[-] to 1.5 gm/kg.

23. (currently amended) The method of claim ~~21~~ 17 or 18 in which the therapeutically effective amount is about 0.28[-] to 0.42 gm/kg.

24. (currently amended) The method of claim ~~24~~17 or 18 in which the liposomes are administered once.

25. (currently amended) The method of claim ~~24~~17 or 18 in which the liposomes are administered more than once.

26. (currently amended) The method of claim ~~24~~17 or 18 in which the liposomes are administered in repeated doses.

27. (currently amended) The method of claim ~~24~~17 or 18 in which said liposomes are administered weekly.

28. (currently amended) The method of claim ~~24~~17 or 18 in which said liposomes are administered ~~one dose~~ once per week for 4 to 16 weeks.

29. (currently amended) The method of claim ~~24~~17 or 18 in which said liposomes are administered ~~one dose~~ once per week for 10 weeks.

Claims 30-43 (cancelled)